New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.

@article{Wu2017NewDO,
  title={New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.},
  author={Ting-Hui Wu and Emily Han-Chung Hsiue and J Lee and C R Lin and James C Yang},
  journal={Expert review of respiratory medicine},
  year={2017},
  volume={11 1},
  pages={51-55}
}
INTRODUCTION Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon 20 insertions. The clinical significance, particularly their response to EGFR tyrosine kinase inhibitors (TKIs) is largely unclear. Previous data is limited to a small fraction of patients in prospective studies and retrospective series. Recently, a combined… CONTINUE READING